Skip to Main Content
TABLE 3

Integrated incretin hormone responses (total and intact GLP-1 and total and intact GIP) to oral glucose (50 g in 400 ml H2O) and adjustable (isoglycemic) intravenous glucose infusion (20% wt/vol) in patients with chronic pancreatitis and secondary diabetes, patients with chronic pancreatitis and NGT, patients with type 2 diabetes, and healthy subjects

Integrated incretin hormone responsesPatients with chronic pancreatitis and diabetesPatients with chronic pancreatitis and NGTPatients with type 2 diabetesHealthy subjects
n (F/M) 8/6 8/6 8/6 8/6 
Total GLP-1 (nmol/l × 4 h)     
        Oral 3.3 ± 0.4 2.6 ± 0.6 1.1 ± 0.5 1.0 ± 0.3 
        Intravenous 0.5 ± 0.4 −0.1 ± 1.0 −0.5 ± 0.1 0.1 ± 0.1 
        Oral-intravenous 3.0 ± 0.8* 2.7 ± 1.2* 1.6 ± 0.4* 0.9 ± 0.3* 
Intact GLP-1 (pmol/l × 4 h)     
        Oral 211 ± 138 161 ± 60 11 ± 130 138 ± 39 
        Intravenous −103 ± 58 −176 ± 213 −167 ± 157 −98 ± 28 
        Oral-intravenous 314 ± 144* 336 ± 207 177 ± 129 235 ± 53* 
Total GIP (nmol/l × 4 h)     
        Oral 10.6 ± 2.0 7.7 ± 2.3 5.4 ± 0.5 6.3 ± 1.1 
        Intravenous −0.2 ± 0.3 −1.0 ± 0.5 −1.8 ± 0.7 −0.8 ± 0.3 
        Oral-intravenous 10.8 ± 2.0* 8.7 ± 2.1* 7.2 ± 0.8* 7.1 ± 1.0* 
Intact GIP (pmol/l × 4 h)     
        Oral 4.0 ± 0.7§ 2.2 ± 0.5 2.2 ± 0.3 2.5 ± 0.5 
        Intravenous 0.1 ± 0.2 0.0 ± 0.3 −0.2 ± 0.3 −0.8 ± 0.5 
        Oral-intravenous 3.8 ± 0.7* 2.2 ± 0.5* 2.4 ± 0.3* 3.2 ± 0.3* 
Integrated incretin hormone responsesPatients with chronic pancreatitis and diabetesPatients with chronic pancreatitis and NGTPatients with type 2 diabetesHealthy subjects
n (F/M) 8/6 8/6 8/6 8/6 
Total GLP-1 (nmol/l × 4 h)     
        Oral 3.3 ± 0.4 2.6 ± 0.6 1.1 ± 0.5 1.0 ± 0.3 
        Intravenous 0.5 ± 0.4 −0.1 ± 1.0 −0.5 ± 0.1 0.1 ± 0.1 
        Oral-intravenous 3.0 ± 0.8* 2.7 ± 1.2* 1.6 ± 0.4* 0.9 ± 0.3* 
Intact GLP-1 (pmol/l × 4 h)     
        Oral 211 ± 138 161 ± 60 11 ± 130 138 ± 39 
        Intravenous −103 ± 58 −176 ± 213 −167 ± 157 −98 ± 28 
        Oral-intravenous 314 ± 144* 336 ± 207 177 ± 129 235 ± 53* 
Total GIP (nmol/l × 4 h)     
        Oral 10.6 ± 2.0 7.7 ± 2.3 5.4 ± 0.5 6.3 ± 1.1 
        Intravenous −0.2 ± 0.3 −1.0 ± 0.5 −1.8 ± 0.7 −0.8 ± 0.3 
        Oral-intravenous 10.8 ± 2.0* 8.7 ± 2.1* 7.2 ± 0.8* 7.1 ± 1.0* 
Intact GIP (pmol/l × 4 h)     
        Oral 4.0 ± 0.7§ 2.2 ± 0.5 2.2 ± 0.3 2.5 ± 0.5 
        Intravenous 0.1 ± 0.2 0.0 ± 0.3 −0.2 ± 0.3 −0.8 ± 0.5 
        Oral-intravenous 3.8 ± 0.7* 2.2 ± 0.5* 2.4 ± 0.3* 3.2 ± 0.3* 

Data are means ± SE. Significant differences between incretin responses to oral glucose and isoglycemic intravenous glucose infusion within each group (P < 0.05) and significant differences in incretin responses between the four groups are indicated.

*

P < 0.05;

P < 0.05 compared with patients with type 2 diabetes and healthy subjects;

P < 0.05 compared with patients with chronic pancreatitis and diabetes;

§

P < 0.05 compared with patients with chronic pancreatitis and NGT, patients with type 2 diabetes, and healthy subjects.

Close Modal

or Create an Account

Close Modal
Close Modal